Molnupiravir has an emergency use permit (EUA) from the Food and Drug Administration (BPOM). At the same time, Health Minister Budi Gunadi Sadikin said that his party guarantees that the stock of Molnupiravir is safe when the third wave of COVID-19 arrives. It is predicted that the peak of the wave due to the Omicron variant will occur next February.
“Now we are ready, there are around 400 thousand tablets that have been imported by Hetero,” said the Minister of Health when met in Bekasi, Friday (14/1/2022).
BPOM announced the issuance of an emergency use of authorization (EUA) for the drug Molnupiravir in the form of 200 mg capsules registered by PT Amarox Pharma Global and produced by Hetero Labs Ltd, India, Thursday (13/1/2022).
The drug is indicated for the treatment of mild to moderate COVID-19 in patients aged 18 years and over without oxygen administration and an increased risk of developing severe COVID-19 infection. The drug is given twice a day as much as 4 capsules (@200 mg) for 5 (five) days.
What are the side effects like?
BPOM said that based on the evaluation results from the safety aspect, Molnupiravir is relatively safe to use with the risk of side effects that can be tolerated. The following is a list of the most commonly reported side effects:
- Abdominal pain
- Oropharyngeal pain
“In addition, the results of non-clinical trials and clinical trials, Molnupiravir does not cause liver function disorders. However, Molnupiravir should not be used in pregnant women and for women of childbearing age who are not pregnant should use contraception while giving Molnupiravir,” explained BPOM in a statement. written, Thursday (13/1).
Watch Videos “UK First Country To Use Molnupiravir As Covid-19 Drug“
(vyp / naf)
The post Molnupiravir Side Effects, RI’s COVID-19 ‘Weapon’ Pill Faces the Omicron Wave appeared first on Newsy Today.